Sulbactam/ampicillin in paediatric infections

Area of Science:

• Clinical microbiology
• Pediatric infectious diseases
• Pharmacology

Background:

• Ampicillin resistance in Haemophilus influenzae type b has limited ampicillin use in treating serious childhood infections.
• Alternative therapies like chloramphenicol or third-generation cephalosporins are often employed, but may have limitations.

Purpose of the Study:

• To evaluate the efficacy of sulbactam/ampicillin in restoring ampicillin's utility.
• To assess the expanded spectrum of activity of sulbactam/ampicillin against resistant bacteria.
• To explore its potential in treating various pediatric infections.

Main Methods:

• The study focuses on the in vitro and clinical implications of combining ampicillin with sulbactam.
• Comparative analysis of sulbactam/ampicillin against third-generation cephalosporins and ampicillin for specific bacterial pathogens.

Main Results:

• Sulbactam/ampicillin restores ampicillin's effectiveness and broadens its spectrum to include ampicillin-resistant Staphylococcus aureus.
• The combination demonstrates superior efficacy against Listeria and enterococci compared to third-generation cephalosporins.
• It shows enhanced activity against Enterobacteriaceae compared to ampicillin alone.

Conclusions:

• Sulbactam/ampicillin is a valuable therapeutic option for bacterial meningitis in children.
• This combination shows promise for treating soft tissue, bone, and joint infections in pediatric patients.
• It represents an effective strategy against ampicillin-resistant Gram-positive and Gram-negative bacteria.